Abstract: The invention relates generally to naphthyridine derivatives of the formula wherein one of U, X, Y and Z is nitrogen and the others are C—R, where R is hydrogen or a substituent. More specifically, the invention relates to 1,6-naphthyridine derivatives and pharmaceutical compositions containing such derivatives. Methods of the invention comprise administration of a naphthyridine derivative of the invention for the treatment of diabetes and related disorders.

Abstract: The invention relates to novel substituted thien-3-yl-sulphonylamino(thio)carbonyl-triazolin(ethi)ones of the general formula (I) in which Q1, Q2, R1, R2, R3 and R4 are each as defined in the description, and to salts of the compounds according to formula (I), to processes and to novel intermediates for their preparation and to their use as herbicides.

Abstract: The present invention provides a process for joining plastics components by a combination of pressing and laser welding, wherein, at the joining points (1) of the components (3, 4), at least a first component (3) has a resilient and/or compressible sealing lip (5), wherein the sealing lip (5) is resiliently deformed by pressing the components (3, 4) together, while the external pressure is maintained, the laser beam is directed onto the joining point (1) and, by purposeful irradiation of the joining point (1), the components (3, 4) are joined together.

Abstract: The present invention describes a process for preparing 4-amino-1-naphthol ethers which is characterized in that naphthol ethers are first prepared from 1-naphthols, the former are then converted to the corresponding 4-acetamino-1-naphthol ethers and then the acyl group is cleaved off, and further describes 4-acetamino-1-naphthol ethers obtained thereby.

Abstract: The present invention relates to a herbicide combination comprising components (A) and (B), where (A) is one or more herbicides from the group of the compounds of the formula (I) or salts thereof in which R1, R2, R3, R4, R5, R6, R7, R8 and A are as defined in claim 1; and (B) is one or more herbicides different from herbicide (A), preferably from the group of compounds consisting of (B1) herbicides which can be employed selectively and which are effective mainly against monocotyledonous and dicotyledonous harmful plants, (B2) herbicides which can be employed selectively and which are effective mainly against dicotyledonous harmful plants and (B3) herbicides which can be employed selectively and which are effective mainly against monocotyledonous harmful plants, (B4) herbicides which can be employed non-selectively and which are effective against monocotyledonous and dicotyledonous harmful plants, for example for use in the non-selective field or in crops which are specifically tolerant.

Abstract: The present invention relates to heat and storage stable vinyl polymer polyol secondary dispersions containing A) at least one vinyl polymer resin having functional groups selected from hydroxyl, carboxyl and/or sulfonic acid groups and dispersed in a water/solvent mixture in the presence of a neutralizing agent, and B) at least one amphiphilic polymer built up from a hydrophobic and a hydrophilic segment. The invention also relates to a process for the preparation of the vinyl polymer polyol secondary dispersions by preparing vinyl polymer resin A) by polymerizing a mixture of ethylenically unsaturated monomers a) in the presence of an initiator b) in a water/solvent mixture and adding at least one amphiphilic polymer B), then at least partly neutralizing and dispersing the resulting product, optionally after the addition of a further amount of water.

Abstract: This invention relates to methods of treatment of cardiovascular disorders, thromboembolic disorders, inflammation, and disorders of the central nervous system using pyrazol pyridine derivatives of formula (I) wherein R1 is a radical of the formula —O—SO2-R3 in which R3 is optionally substituted C1-6-alkyl, optionally substituted C3-8-cycloalkyl, or optionally substituted phenyl; R2 is H, optionally substituted C1-6-alkyl-CO— or optionally substituted C1-6-alkyl-SO2—; as well as salts, stereoisomers, tautomers, and hydrates thereof.

Abstract: Reagents that regulate human BMP-2 inducible kinase and reagents which bind to human BMP-2 inducible kinase gene products can play a role in preventing, ameliorating, or correcting dysfunctions or diseases including, but not limited to, cancer, diabetes, CNS disorders, COPD, gastrointestinal disorders, and cardiovascular disorders.

Abstract: A device and a process are described for membrane electrophoresis or electrofiltration. The device contains at least one input chamber, one output chamber, and one cathode chamber and anode chamber each, whereby the individual chambers are separated from one another by membranes, and are integrated into a permanently attached module with membranes, and whereby the electrodes are integrated into the module, and the module is connected to constructions enabling continuous flow through the input and output chambers, as well as through the electrode chambers. It is emphasized that this abstract is provided to comply with the rules requiring an abstract which will allow a searcher or other reader quickly to ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the appended issued claims. 37 CFR §1.72(b).

Abstract: Aqueous coating compositions based on polyurethane dispersions which cure under the influence of high-energy radiation, to a process for preparing them and to their use. The coating compositions contain a polyisocyanate, a polyurethane containing free-radically polymerizable groups, and an initiator which is capable of initiating a free-radical polymerization.

Abstract: A thermoplastic molding composition especially suitable for preparing extruded articles is disclosed. The composition contains polycarbonate, a fatty acid ester and a triazine conforming to formula (I) wherein R1, R2, R3 and R4 independently one of the others is selected from the group consisting of C1-C8-alkyl, halogen and —CN, and where R5 is H or C1-C20-alkyl.

Abstract: This invention relates to substituted imidazole derivatives which have been found to suppress appetite and induce weight loss. The invention also provides methods for synthesis of the compounds, pharmaceutical compositions comprising the compounds, and methods of using such compositions for inducing weight loss and treating obesity and obesity-related disorders.

Abstract: A halogenated butyl polymer having improved properties, the butyl polymer derived from a monomer mixture comprising a C4 to C8 monoolefin monomer, a C4 to C14 multiolefin monomer and a styrenic monomer with a catalyst system to produce the butyl polymer. The improved properties include faster cure, higher maximum torque, higher delta torque, relatively stable modulus over time, improved hot air aging properties and improved aged flexure properties. These improved properties are believed to result from direct interaction between the styrenic moieties in the polymer backbone with a crosslinking agent added to vulcanize the halogenated butyl rubber.

Abstract: A test sensor having a pair of electrodes and a reagent for electrochemically measuring the concentration of the analyte in a liquid sample. The test sensor comprises a capillary channel for collecting the liquid sample and a conductor disposed outside the capillary channel. The conductor is in fluid communication with the capillary channel. The liquid test sample is collected and moved through the capillary channel. The liquid test sample contacts the conductor when the capillary channel is substantially full to signal a full condition.

Abstract: Hetero-tetrahydroquinolines can be prepared either by condensing correspondingly substituted hetero-tetrahydroquinoline aldehydes with the desired substituent or by reducing the corresponding keto-substituted hetero-tetrahydroquinolines, followed by introduction of the desired substituent by customary methods. The hetero-tetrahydroquinolines are suitable for use as active compounds in medicaments, in particular in medicaments for treating artheriosclerosis and dyslipidaemias.

Abstract: The present invention relates to a herbicide-safener combination, comprising (A) one or more compounds of the formula (I) or salts thereof in which A is nitrogen or a CR11 grouping, where R11 is hydrogen, alkyl, halogen and haloalkyl, R1 is hydrogen or an optionally substituted radical from the group consisting of alkyl, alkoxy, alkoxyalkyl, alkenyl, akynyl, cycloalkyl, cycloalkylalkyl, aralkyl and aryl, R2 is hydrogen, halogen or in each case optionally halogen-substituted alkyl, alkoxy, alkylthio, alkylamino or dialkylamino having in each case 1 to 6 carbon atoms, R3 is hydrogen, halogen or in each case optionally halogen-substituted alkyl, alkoxy, alkylthio, alkylamino or dialkylamino having in each case 1 to 6 carbon atoms, R4—R7 independently of one another are hydrogen, halogen, cyano, thiocyanato or in each case optionally halogen-substituted alkyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, alkylcarbonyl, alkoxycarbonyl, alkylaminocarbonyl having in each case 1 to 3 car

Abstract: The invention relates to the use of compounds of the formula (I) and salts thereof for the selective control of unwanted vegetation in leguminous plants or for the non-selective control of unwanted vegetation in which A is nitrogen or a CR11 grouping, where R11 is hydrogen, alkyl, halogen or haloalkyl, R1 is hydrogen optionally substituted radical from the group consisting of alkyl alkoxy, alkoxyalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aralkyl and aryl, R2 hydrogen, halogen or is in each case optionally halogen-substituted alkyl, alkoxy, alkylthio, alkylamino or dialkylamino having in each case 1 to 6 carbon atoms, R3 is hydrogen, halogen or is in each case optionally halogen-substituted alkyl, alkoxy, alkylthio, alkylamino or dialkylamino having in each case 1 to 6 carbon atoms, R4—R7 independently of one another are hydrogen, halogen, cyano, thiocyanato or are in each case optionally halogen-substituted alkyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, alkylcarbo

Abstract: The present invention relates to the use of known 2-phenyl-substituted imidazotriazinones having short, unbranched alkyl radicals in the 9-position and cGMP PDE-inhibitory properties for the production of medicaments for the treatment of cardiac insufficiency, psoriasis, female infertility, cancer, diabetes, ophthalmic disorders such as glaucoma, disorders of gastric motility, cystic fibrosis, premature labour, pulmonary hypertension, bladder disorders, prostate hyperplasia, nitrate-induced tolerance, pre-eclampsia, alopecia, Parkinson's disease, pain, tinnitus or the renal syndrome.

Abstract: An improved process for the purification of antibodies from human plasma or other sources is disclosed. The process involves suspension of the antibodies at pH 3.8 to 4.5 followed by addition of caprylic acid and a pH shift to pH 5.0 to 5.2. A precipitate of contaminating proteins, lipids and caprylate forms and is removed, while the majority of the antibodies remain in solution. Sodium caprylate is again added to a final concentration of not less than about 15 mM. This solution is incubated for 1 hour at 25° C. to effect viral inactivation. A precipitate (mainly caprylate) is removed and the clear solution is diluted with purified water to reduce ionic strength. Anion exchange chromatography using two different resins is utilized to obtain an exceptionally pure IgG with subclass distribution similar to the starting distribution. The method maximizes yield and produces a gamma globulin with greater than 99% purity. The resin columns used to obtain a high yield of IgG retain IgM and IgA.

Abstract: The invention is directed to a polypeptide comprising a human IL-2 mutein numbered in accordance with wild-type IL-2 wherein said human IL-2 is substituted at at least one of positions 20, 88 or 126, whereby said mutein preferentially activates T cells over NK cells. D20H and I, N88G, I, and R, in particular have a relative T cell-differential activity much greater than native IL-2, with predicted associated reduced in vivo toxicity. The invention also includes polynucleotides coding for the muteins of the invention, vectors containing the polynucleotides, transformed host cells, pharmaceutical compositions comprising the muteins, and therapeutic methods of treatment.